News
.jpeg)
Serum Institute of India to produce up to 100 million Covid-19 vaccine doses for India and low- and middle-income Countries as early as 2021
ABLE member and one of the largest global vaccine manufacturers by volume, Serum Institute of India (SII), has entered into a new landmark partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries (LMICs).
Bangalore Bioinnovation Centre showcases 8 products developed at its facility
ABLE member and a leading biotech incubator in Bangalore, The Bangalore Bioinnovation Centre, has announced launch of several products to help fight against covid-19. These products were developed by six start-ups from its premises.
.jpeg)
Novavax and Serum Institute of India announce development and commercial collaboration for Covid vaccine
In another development, Novavax Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced a license agreement with Serum Institute of India Private Limited (SIIPL) for the development and commercialization of NVXCoV2373, Novavax’ COVID19 vaccine candidate, in low- and middle-income countries (LMIC) and India.
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.
BioEconomy Conclave 2026
